VTGN · Vistagen Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Venrock Healthcare Capital Partners II, L.P. 10% Owner | ▼ Sell | Open Market | 20,637,286 Shares held | 7/12/2022 | View profile |
| COMMODORE CAPITAL LP 10% Owner | ▲ Buy | Open Market | 1,575,000 Shares held | 8/7/2023 | View profile |
| GIN JERRY B | ▲ Buy | Open Market | 100,000 Shares held | 8/18/2022 | View profile |
| SNODGRASS H. RALPH PRES./CHIEF SCIENTIFIC OFFICER | ▲ Buy | Grant | 64,958 Shares held | 12/31/2021 | View profile |
| Adler Reid G. CHIEF LEGAL OFFICER | ▲ Buy | Grant | 60,868 Shares held | 6/30/2026 | View profile |
| Singh Shawn CHIEF EXECUTIVE OFFICER | ▲ Buy | Grant | 54,846 Shares held | 6/30/2026 | View profile |
| Smith Mark Alan CHIEF MEDICAL OFFICER | ▲ Buy | Grant | 19,915 Shares held | 6/30/2022 | View profile |
| Prince Joshua S. Chief Operating Officer | ▲ Buy | Grant | 15,249 Shares held | 12/31/2025 | View profile |
| Anderson Cynthia Lynn CHIEF FINANCIAL OFFICER | ▲ Buy | Grant | 12,801 Shares held | 6/30/2025 | View profile |
| Tressler Nick B. Chief Financial Officer | ▲ Buy | Grant | 11,712 Shares held | 6/30/2026 | View profile |
| DOTSON JERROLD DUANE VP, CFO AND SECRETARY | ▲ Buy | Grant | 3,671 Shares held | 6/30/2023 | View profile |
Transaction History
| Singh Shawn | ▲ Buy | Grant | 36,818 | $7K | 6/30/2026 |
| Adler Reid G. | ▲ Buy | Grant | 36,818 | $7K | 6/30/2026 |
| Tressler Nick B. | ▲ Buy | Grant | 11,712 | $2K | 6/30/2026 |
| Prince Joshua S. | ▲ Buy | Grant | 4,386 | $2K | 12/31/2025 |
| Prince Joshua S. | ▲ Buy | Grant | 4,882 | $8K | 6/30/2025 |
| Adler Reid G. | ▲ Buy | Grant | 7,541 | $13K | 6/30/2025 |
| Anderson Cynthia Lynn | ▲ Buy | Grant | 6,617 | $11K | 6/30/2025 |
| Singh Shawn | ▲ Buy | Grant | 7,541 | $13K | 6/30/2025 |
| Prince Joshua S. | ▲ Buy | Grant | 3,310 | $8K | 12/31/2024 |
| Anderson Cynthia Lynn | ▲ Buy | Grant | 2,592 | $6K | 12/31/2024 |
| Prince Joshua S. | ▲ Buy | Grant | 2,671 | $8K | 6/28/2024 |
| Anderson Cynthia Lynn | ▲ Buy | Grant | 3,592 | $11K | 6/28/2024 |
| Adler Reid G. | ▲ Buy | Grant | 4,854 | $14K | 6/28/2024 |
| Singh Shawn | ▲ Buy | Grant | 4,854 | $14K | 6/28/2024 |
| Adler Reid G. | ▲ Buy | Grant | 167 | $287 | 12/29/2023 |
| Singh Shawn | ▲ Buy | Grant | 167 | $287 | 12/29/2023 |
| COMMODORE CAPITAL LP | ▲ Buy | Open Market | 775,756 | $18.0M | 8/7/2023 |
| Singh Shawn | ▲ Buy | Grant | 167 | $265 | 6/30/2023 |
| Adler Reid G. | ▲ Buy | Grant | 167 | $265 | 6/30/2023 |
| DOTSON JERROLD DUANE | ▲ Buy | Grant | 167 | $265 | 6/30/2023 |
| DOTSON JERROLD DUANE | ▲ Buy | Grant | 5,000 | $438 | 12/30/2022 |
| Singh Shawn | ▲ Buy | Grant | 5,000 | $438 | 12/30/2022 |
| GIN JERRY B | ▲ Buy | Open Market | 100,000 | $18K | 8/18/2022 |
| GIN JERRY B | ▲ Buy | Open Market | 100,000 | $18K | 8/18/2022 |
| Adler Reid G. | ▲ Buy | Open Market | 300,000 | $51K | 8/17/2022 |
| Singh Shawn | ▲ Buy | Open Market | 600,000 | $103K | 8/17/2022 |
| DOTSON JERROLD DUANE | ▲ Buy | Grant | 5,000 | $4K | 7/30/2022 |
| Venrock Healthcare Capital Partners II, L.P. | ▼ Sell | Open Market | 60,000 | $53K | 7/12/2022 |
| Singh Shawn | ▲ Buy | Grant | 5,000 | $4K | 6/30/2022 |
| Smith Mark Alan | ▲ Buy | Grant | 5,000 | $4K | 6/30/2022 |
| Singh Shawn | ▲ Buy | Option Exercise | 100,000 | $100K | 5/12/2022 |
| DOTSON JERROLD DUANE | ▲ Buy | Option Exercise | 18,750 | $19K | 1/11/2022 |
| Smith Mark Alan | ▲ Buy | Grant | 2,655 | $4K | 12/31/2021 |
| DOTSON JERROLD DUANE | ▲ Buy | Grant | 3,575 | $6K | 12/31/2021 |
| SNODGRASS H. RALPH | ▲ Buy | Grant | 3,623 | $6K | 12/31/2021 |
| Singh Shawn | ▲ Buy | Grant | 3,623 | $6K | 12/31/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
VTGN linked to growing vasomotor symptoms market amid recent price dip
The vasomotor symptoms market is projected to expand through 2036 as adoption of hormonal and non‑hormonal therapies rises, a trend that aligns with VTGN’s focus on treatments for menopausal symptoms. At the same time, VTGN appeared on a recent list of falling stocks that traders are watching, indicating recent price weakness. These factors together provide context for the stock’s current market environment.
VTGN linked to growing vasomotor symptoms market amid recent price dip. The vasomotor symptoms market is projected to expand through 2036 as adoption of hormonal and non‑hormonal therapies rises, a trend that aligns with VTGN’s focus on treatments for menopausal symptoms. At the same time, VTGN appeared on a recent list of falling stocks that traders are watching, indicating recent price weakness. These factors together provide context for the stock’s current market environment.